SOLICITATION NOTICE
68 -- Blood and Bone Marrow Reagents
- Notice Date
- 8/11/2006
- Notice Type
- Solicitation Notice
- NAICS
- 325188
— All Other Basic Inorganic Chemical Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-60142-NG
- Response Due
- 8/21/2006
- Archive Date
- 9/5/2006
- Description
- The National Institutes of Health (NIH), National Cancer Institute (NCI), Center for Cancer Research (CCR) plans to procure on a sole source basis with PSS Bio Instruments Inc, 6052 Industrial Way, Suite H, Livermore, California 94551 blood and bone marrow reagents (kits) catalog number E8000. The supplies and services are commercial herein as defined in FAR Part 12 and this acquisition will be conducted under the simplified acquisition procedures authorized in FAR Part 13. The North American Industry Classification code is 325188 and the business size standard is 1,000 employees. Requirement: Purchase of a minimum of sixty-three (63) reagent kits and a maximum of one-hundred (100) reagent kits: eight (8) seven (7)ml bottles per kit: reagent shelf life shall be a minimum of 6 months from delivery date), with an option to purchase one (1) Magtration 8Lx Automated Nucleic Acid Purification System. The instrument will be used to purify nucleic acid from blood and bone marrow samples. In addition, the instrument must provide low to moderate throughput (5-10 samples/run) that is fully automated with pre-loaded reagent cartridges that can purify nucleic acid (DNA) from large volume starting samples (up to 7 ml). Additionally, this instrument must provide an automated platform and robotics that allows maximum protection from DNA cross-contamination that is paramount in a clinical setting. The instrument is designed to use bar codes for samples, elution tubes, and reagent cartridge identification. The instrument must elute the DNA into a 2-ml Eppendorf-type tube for future use and storage. Total purification time per run must be two (2) hours or less. Period of Performance: Base Year: September 4, 2006 ? September 3, 2007 with four (4), twelve (12) month options. Justification: Background: Laboratory of Pathology performs molecular testing to assist in the diagnosis of a variety of cancers. It is currently the only CLIA and College of American Pathology approved clinical lab within the NCI certified for performing molecular oncology testing on materials from NIH patients. Current molecular testing includes PCR assays for B and T cell clonality in lymphoproliferative diseases, identification of cancer associated viruses (e.g. EBV, HHV-8, HTLV-1,2), and the identification of cancer associated translocations (e.g., BCL-1, BCL-2, EWS-FLI-1, PAX-3-FKHR). All tests are performed for diagnostic purposes and for Cancer Center protocol requirements. To achieve the first step toward the goal of making a diagnosis, the samples submitted must be treated to extract and purify DNA for subsequent polymerase chain reaction analyses. As the only CLIA and CAP certified molecular oncology laboratory in the Cancer Center, we provide support to a number of NCI principle clinical investigators. The majority of samples submitted to our laboratory for analyses are blood and bone marrow aspirates. These samples need to be handled with extreme care to insure that no nucleic acid cross contamination occurs during the DNA isolation, purification, and analyses procedures. To facilitate this work within the NCI, reagents and an automated (robotic) nucleic acid purification system are required for this purpose. As a result of increased workload the molecular diagnostic service requires automated equipment dedicated for this support service. Automation of the DNA extraction procedure will appreciably reduce work load and preparation time, and will improve quality control. It is the government's belief that PSS Bio Instruments, Inc, is the only known source manufacturing a low-moderate throughput (5-10 samples/run), benchtop instrument with the volume flexibility required (up to 7 ml) and technology required for continued research and diagnosis within the NCI. This is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow the NCI to determine if the party can perform this requirement. An original and one copy of the capability statement must be received in the contracting office by 1:00 pm EDT on August 21, 2006 to Malinda Holdcraft, Contract Specialist. All questions must be in writing and can be faxed to 301-402-4513 or sent via email to holdcram@exchange.nih.gov. It is the vendors? responsibility to insure questions have been received. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive and award, contractors must have valid registration/certification in the Central Contractor Registration (CCR), www.ccr.gov and the Online Representations and Certifications Application (ORCA) http://orca.bpn.gov. Please reference NCI-60142-NG on all correspondence. No collect calls.
- Place of Performance
- Address: Contractor location
- Zip Code: 20892
- Country: UNITED STATES
- Zip Code: 20892
- Record
- SN01112568-W 20060813/060811220548 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |